Exact Mass: 327.128
Exact Mass Matches: 327.128
Found 83 metabolites which its exact mass value is equals to given mass value 327.128,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
N-(1-Deoxy-1-fructosyl)phenylalanine
(2S)-3-Phenyl-2-({[(3S,4S,5R)-2,3,4-trihydroxy-5-(hydroxymethyl)oxolan-2-yl]methyl}amino)propanoic acid
Fructose aminoacids are naturally occurring compounds derived from D-fructose and L-aminoacids. They are amadori products resulting from sugar-aminoacid interactions in food products, especially cooked foods [CCD] N-(1-Deoxy-1-fructosyl)phenylalanine is classified as a Natural Food Constituent (code WA) in the DFC.
Clofibride
3-(Dimethylcarbamoyl)propyl 2-(4-chlorophenoxy)-2-methylpropanoic acid
C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent > C98150 - Fibrate Antilipidemic Agent C - Cardiovascular system > C10 - Lipid modifying agents > C10A - Lipid modifying agents, plain > C10AB - Fibrates
3-(5-Isopropyl-3,8-dimethylazulen-1-yl)-2-(methylsulfonyl)acrylonitrile
3-(5-Isopropyl-3,8-dimethylazulen-1-yl)-2-(methylsulfonyl)acrylonitrile
methyl N-{4-[(alpha-L-rhamnopyranosyl)benzyl]}carbamate
methyl N-{4-[(alpha-L-rhamnopyranosyl)benzyl]}carbamate
Befunolol hydrochloride
Befunolol hydrochloride
D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists
7-(Dipropylamino)-5,6,7,8-tetrahydro-2-naphthalenol hydrobromide (1:1)
7-(Dipropylamino)-5,6,7,8-tetrahydro-2-naphthalenol hydrobromide (1:1)
METHYL2-DEOXY-2-[[(PHENYLMETHOXY)CARBONYL]AMINO]-ALPHA-D-GLUCOPYRANOSIDE
METHYL2-DEOXY-2-[[(PHENYLMETHOXY)CARBONYL]AMINO]-ALPHA-D-GLUCOPYRANOSIDE
METHYL 2-FLUORO-3-(PYRROLIDINE-1-CARBONYL)-[1,1-BIPHENYL]-3-CARBOXYLATE
METHYL 2-FLUORO-3-(PYRROLIDINE-1-CARBONYL)-[1,1-BIPHENYL]-3-CARBOXYLATE
2-N-BOC-3-(3-CHLORO-PHENYL)-2-METHYLAMINOMETHYL-PROPIONIC ACID
2-N-BOC-3-(3-CHLORO-PHENYL)-2-METHYLAMINOMETHYL-PROPIONIC ACID
METHYL 2-N-BOC-2-AMINOMETHYL-3-(4-CHLORO-PHENYL)-PROPIONATE
METHYL 2-N-BOC-2-AMINOMETHYL-3-(4-CHLORO-PHENYL)-PROPIONATE
2-methoxy-N-[(1-methylpyrrolidin-2-yl)methyl]-5-sulfamoylbenzamide
2-methoxy-N-[(1-methylpyrrolidin-2-yl)methyl]-5-sulfamoylbenzamide
N-[(2R,3S)-2-(2,5-Difluorophenyl)tetrahydro-5-oxo-2H-pyran-3-yl]carbamic acid 1,1-dimethylethyl ester
N-[(2R,3S)-2-(2,5-Difluorophenyl)tetrahydro-5-oxo-2H-pyran-3-yl]carbamic acid 1,1-dimethylethyl ester
7-(DIPROPYLAMINO)-5,6,7,8-TETRAHYDRONAPHTHALEN-2-OL HYDROBROMIDE
7-(DIPROPYLAMINO)-5,6,7,8-TETRAHYDRONAPHTHALEN-2-OL HYDROBROMIDE
8-Hydroxy-DPAT hydrobromide
8-Hydroxy-DPAT hydrobromide
8-OH-DPAT (8-Hydroxy-DPAT) hydrobromide is a potent and selective 5-HT1A agonist with a pIC50 of 8.19. 8-OH-DPAT hydrobromide has selectivity of almost 1000 fold for a subtype of the 5-HT1 binding site[1].
METHYL 2-N-BOC-2-AMINOMETHYL-3-(3-CHLORO-PHENYL)-PROPIONATE
METHYL 2-N-BOC-2-AMINOMETHYL-3-(3-CHLORO-PHENYL)-PROPIONATE
5-(Aminosulfonyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-hydroxybenzamide
5-(Aminosulfonyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-hydroxybenzamide
1-[2-(Methylsulfonyl)ethyl]-6-oxo-1,6-dihydropyridine-3-boronic Acid Pinacol Ester
1-[2-(Methylsulfonyl)ethyl]-6-oxo-1,6-dihydropyridine-3-boronic Acid Pinacol Ester
N-(2-Methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanesulfonamide
N-(2-Methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanesulfonamide
1-(5-(TERT-BUTYL)ISOXAZOL-3-YL)-3-(2-(TRIFLUOROMETHYL)PHENYL)UREA
1-(5-(TERT-BUTYL)ISOXAZOL-3-YL)-3-(2-(TRIFLUOROMETHYL)PHENYL)UREA
5-(2-Phenylpyrazolo[1,5-A]pyridin-3-YL)-1H-pyrazolo[3,4-C]pyridazin-3-amine
5-(2-Phenylpyrazolo[1,5-A]pyridin-3-YL)-1H-pyrazolo[3,4-C]pyridazin-3-amine
FR 180204 is an ATP-competitive and selective ERK inhibitor. FR 180204 inhibits ERK1 and ERK2 with IC50s of 0.51 μM (Ki=0.31 μM) and 0.33 μM (Ki=0.14 μM), respectively[1].
(1r)-2-Phenylacetamido-2-(3-carboxyphenyl)ethyl boronic acid
(1r)-2-Phenylacetamido-2-(3-carboxyphenyl)ethyl boronic acid
2-(2-Hydroxy-biphenyl-3-yl)-1H-indole-5-carboxamidine
2-(2-Hydroxy-biphenyl-3-yl)-1H-indole-5-carboxamidine
clofibride
clofibride
C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent > C98150 - Fibrate Antilipidemic Agent C - Cardiovascular system > C10 - Lipid modifying agents > C10A - Lipid modifying agents, plain > C10AB - Fibrates
[8-Methoxy-2-(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl]-piperidin-1-ylmethanone
[8-Methoxy-2-(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl]-piperidin-1-ylmethanone
1-Quinolin-8-yl-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-carbaldehyde
1-Quinolin-8-yl-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-carbaldehyde
5-(4-methyl-1-naphthalenyl)-N-phenyl-2-furancarboxamide
5-(4-methyl-1-naphthalenyl)-N-phenyl-2-furancarboxamide
3-(2,5-Dimethyl-3-furanyl)-5,6-diphenyl-1,2,4-triazine
3-(2,5-Dimethyl-3-furanyl)-5,6-diphenyl-1,2,4-triazine
3-[2-Methoxy-6-(4-methoxyphenyl)-3-pyridinyl]-5-(methoxymethyl)-1,2,4-oxadiazole
3-[2-Methoxy-6-(4-methoxyphenyl)-3-pyridinyl]-5-(methoxymethyl)-1,2,4-oxadiazole
3-(4-oxo-1H-quinazolin-2-yl)propanoic acid (3,5-dimethyl-4-isoxazolyl)methyl ester
3-(4-oxo-1H-quinazolin-2-yl)propanoic acid (3,5-dimethyl-4-isoxazolyl)methyl ester
4-[4-[(4-Fluorophenyl)methyl]-1-piperidinyl]thieno[2,3-d]pyrimidine
4-[4-[(4-Fluorophenyl)methyl]-1-piperidinyl]thieno[2,3-d]pyrimidine
2-[(3S,6aS,8S,10aS)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2-thiazolyl)acetamide
2-[(3S,6aS,8S,10aS)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2-thiazolyl)acetamide
2-[(3S,6aS,8R,10aS)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2-thiazolyl)acetamide
2-[(3S,6aS,8R,10aS)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2-thiazolyl)acetamide
2-[(3S,6aR,8S,10aR)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-(1,3-thiazol-2-yl)acetamide
2-[(3S,6aR,8S,10aR)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-(1,3-thiazol-2-yl)acetamide
2-[(3R,6aS,8S,10aS)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2-thiazolyl)acetamide
2-[(3R,6aS,8S,10aS)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2-thiazolyl)acetamide
2-[(3S,6aR,8R,10aR)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-(1,3-thiazol-2-yl)acetamide
2-[(3S,6aR,8R,10aR)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-(1,3-thiazol-2-yl)acetamide
2-[(3R,6aR,8S,10aR)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2-thiazolyl)acetamide
2-[(3R,6aR,8S,10aR)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2-thiazolyl)acetamide
2-[(3R,6aR,8R,10aR)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2-thiazolyl)acetamide
2-[(3R,6aR,8R,10aR)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2-thiazolyl)acetamide
2-[(3R,6aS,8R,10aS)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2-thiazolyl)acetamide
2-[(3R,6aS,8R,10aS)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2-thiazolyl)acetamide
N-butyl-N(2)-[(2Z)-2-(2-furyl)-2-(methoxyimino)acetyl]-L-cysteinamide
N-butyl-N(2)-[(2Z)-2-(2-furyl)-2-(methoxyimino)acetyl]-L-cysteinamide
N(2)-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]-N-butyl-L-alaninamide
N(2)-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]-N-butyl-L-alaninamide
7-(diethylamino)-3,4-dioxo-10H-phenoxazine-1-carboxamide
7-(diethylamino)-3,4-dioxo-10H-phenoxazine-1-carboxamide
N-(1-Deoxy-1-fructosyl)phenylalanine
N-(1-Deoxy-1-fructosyl)phenylalanine
An L-phenylalanine derivative in which one of the amino hydrogens of L-phenylalanine has been replaced by a 1-fructosyl group.
GLUT1-IN-2
GLUT1-IN-2
GLUT1-IN-2 (compound 17) is a GLUT1 inhibitor with an IC50 value of 12 μM. GLUT1-IN-2 shows inhibitory effect to Plasmodium falciparum hexose transporter PfHT with an IC50 value of 13 μM. GLUT1-IN-2 can be used for the research of infection[1].
(e,2e)-3-(1h-indol-3-yl)-n-[(1e)-2-(1h-indol-3-yl)ethenyl]prop-2-enimidic acid
(e,2e)-3-(1h-indol-3-yl)-n-[(1e)-2-(1h-indol-3-yl)ethenyl]prop-2-enimidic acid
n-[(4-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}phenyl)methyl]methoxycarboximidic acid
n-[(4-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}phenyl)methyl]methoxycarboximidic acid
(1r,4r,5s)-4-(2-chloroethyl)-1-[(s)-(1s)-cyclohex-2-en-1-yl(hydroxy)methyl]-5-ethyl-3-hydroxy-6-oxa-2-azabicyclo[3.2.0]hept-2-en-7-one
(1r,4r,5s)-4-(2-chloroethyl)-1-[(s)-(1s)-cyclohex-2-en-1-yl(hydroxy)methyl]-5-ethyl-3-hydroxy-6-oxa-2-azabicyclo[3.2.0]hept-2-en-7-one
4-(2-chloroethyl)-1-[cyclohex-2-en-1-yl(hydroxy)methyl]-5-ethyl-3-hydroxy-6-oxa-2-azabicyclo[3.2.0]hept-2-en-7-one
4-(2-chloroethyl)-1-[cyclohex-2-en-1-yl(hydroxy)methyl]-5-ethyl-3-hydroxy-6-oxa-2-azabicyclo[3.2.0]hept-2-en-7-one
6-hydroxy-4-[(4r,5s,6r)-5-hydroxy-6-[(2s,3r)-2-hydroxy-3-methyl-4-methylideneoxolan-2-yl]-1,3-dioxan-4-yl]-4,5-dihydro-3h-pyridin-2-one
6-hydroxy-4-[(4r,5s,6r)-5-hydroxy-6-[(2s,3r)-2-hydroxy-3-methyl-4-methylideneoxolan-2-yl]-1,3-dioxan-4-yl]-4,5-dihydro-3h-pyridin-2-one
n-[(4-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}phenyl)methyl]methoxycarboximidic acid
n-[(4-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}phenyl)methyl]methoxycarboximidic acid
(2e)-3-(1h-indol-3-yl)-n-[2-(1h-indol-3-yl)ethenyl]prop-2-enimidic acid
(2e)-3-(1h-indol-3-yl)-n-[2-(1h-indol-3-yl)ethenyl]prop-2-enimidic acid
3-(carboxymethyl)-4-[(1z)-1-(3-hydroxy-4-methyl-5-oxooxolan-2-yl)prop-1-en-2-yl]pyrrolidine-2-carboxylic acid
3-(carboxymethyl)-4-[(1z)-1-(3-hydroxy-4-methyl-5-oxooxolan-2-yl)prop-1-en-2-yl]pyrrolidine-2-carboxylic acid
6-hydroxy-4-[5-hydroxy-6-(2-hydroxy-3-methyl-4-methylideneoxolan-2-yl)-1,3-dioxan-4-yl]-4,5-dihydro-3h-pyridin-2-one
6-hydroxy-4-[5-hydroxy-6-(2-hydroxy-3-methyl-4-methylideneoxolan-2-yl)-1,3-dioxan-4-yl]-4,5-dihydro-3h-pyridin-2-one
(z,2e)-3-(1h-indol-3-yl)-n-[(1z)-2-(1h-indol-3-yl)ethenyl]prop-2-enimidic acid
(z,2e)-3-(1h-indol-3-yl)-n-[(1z)-2-(1h-indol-3-yl)ethenyl]prop-2-enimidic acid
6-hydroxy-4-[(5r,6s)-5-hydroxy-6-[(2r,3r)-2-hydroxy-3-methyl-4-methylideneoxolan-2-yl]-1,3-dioxan-4-yl]-4,5-dihydro-3h-pyridin-2-one
6-hydroxy-4-[(5r,6s)-5-hydroxy-6-[(2r,3r)-2-hydroxy-3-methyl-4-methylideneoxolan-2-yl]-1,3-dioxan-4-yl]-4,5-dihydro-3h-pyridin-2-one
n-({4-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]phenyl}methyl)methoxycarboximidic acid
n-({4-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]phenyl}methyl)methoxycarboximidic acid
3-(1h-indol-3-yl)-n-[2-(1h-indol-3-yl)ethenyl]prop-2-enimidic acid
3-(1h-indol-3-yl)-n-[2-(1h-indol-3-yl)ethenyl]prop-2-enimidic acid
6-hydroxy-4-[(4r,5s,6r)-5-hydroxy-6-[(2r,3r)-2-hydroxy-3-methyl-4-methylideneoxolan-2-yl]-1,3-dioxan-4-yl]-4,5-dihydro-3h-pyridin-2-one
6-hydroxy-4-[(4r,5s,6r)-5-hydroxy-6-[(2r,3r)-2-hydroxy-3-methyl-4-methylideneoxolan-2-yl]-1,3-dioxan-4-yl]-4,5-dihydro-3h-pyridin-2-one
7-methoxy-4-{3h,4h,9h-pyrido[3,4-b]indol-1-yl}quinoline
7-methoxy-4-{3h,4h,9h-pyrido[3,4-b]indol-1-yl}quinoline
6-hydroxy-4-[(4r,5s,6r)-5-hydroxy-6-[(2s,3s)-2-hydroxy-3-methyl-4-methylideneoxolan-2-yl]-1,3-dioxan-4-yl]-4,5-dihydro-3h-pyridin-2-one
6-hydroxy-4-[(4r,5s,6r)-5-hydroxy-6-[(2s,3s)-2-hydroxy-3-methyl-4-methylideneoxolan-2-yl]-1,3-dioxan-4-yl]-4,5-dihydro-3h-pyridin-2-one
